Citadel Advisors
AVIR icon

Citadel Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

Citadel Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$260K Buy
48,401
+5,710
+13% +$26.2K ﹤0.01% 10798
2025
Q4 		$152K Buy
42,691
+962
+2% +$3.06K ﹤0.01% 11300
2025
Q3 		$121K Buy
+41,729
New +$142K ﹤0.01% 11700
2025
Q2 		– Sell
-21,992
Closed -$65.8K – 12492
2025
Q1 		$65.8K Sell
21,992
-196,796
-90% -$614K ﹤0.01% 12005
2024
Q4 		$733K Sell
218,788
-376,461
-63% -$1.25M ﹤0.01% 7705
2024
Q3 		$1.99M Buy
595,249
+69,646
+13% +$253K ﹤0.01% 5538
2024
Q2 		$1.74M Buy
525,603
+329,603
+168% +$1.23M ﹤0.01% 5577
2024
Q1 		$792K Buy
196,000
+22,986
+13% +$90K ﹤0.01% 7415
2023
Q4 		$528K Sell
173,014
-411,674
-70% -$1.25M ﹤0.01% 7974
2023
Q3 		$1.75M Sell
584,688
-897,095
-61% -$3.05M ﹤0.01% 5467
2023
Q2 		$5.54M Sell
1,481,783
-99,925
-6% -$374K ﹤0.01% 3495
2023
Q1 		$5.3M Buy
1,581,708
+975,523
+161% +$3.96M ﹤0.01% 3710
2022
Q4 		$2.92M Buy
606,185
+313,381
+107% +$1.59M ﹤0.01% 4786
2022
Q3 		$1.67M Buy
292,804
+33,750
+13% +$258K ﹤0.01% 5940
2022
Q2 		$1.84M Sell
259,054
-1,295,171
-83% -$8.84M ﹤0.01% 5705
2022
Q1 		$11.2M Sell
1,554,225
-114,707
-7% -$779K ﹤0.01% 2769
2021
Q4 		$14.9M Buy
1,668,932
+1,569,450
+1,578% +$24.5M ﹤0.01% 2425
2021
Q3 		$3.49M Buy
99,482
+42,001
+73% +$1.16M ﹤0.01% 5034
2021
Q2 		$1.24M Buy
57,481
+53,467
+1,332% +$1.61M ﹤0.01% 7777
2021
Q1 		$248K Sell
4,014
-164,191
-98% -$11.1M ﹤0.01% 11248
2020
Q4 		$7.03M Buy
+168,205
New +$5.42M ﹤0.01% 3118

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors's AVIR Position: Q1 2026 in Review

Citadel Advisors increased its Atea Pharmaceuticals (AVIR) stake by 13% in Q1 2026, buying an estimated $26.2K and bringing the position to 48,401 shares worth $260K. The position accounts for ﹤0.01% of the portfolio, ranked #10798.

Citadel Advisors first reported a position in AVIR in Q4 2020 and has held it in 21 quarters since. The position peaked at $14.9M in Q4 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Citadel Advisors held 48,401 shares of Atea Pharmaceuticals worth $260K as of Q1 2026.
  • Citadel Advisors bought 5,710 Atea Pharmaceuticals shares in Q1 2026, an estimated $26.2K.
  • Atea Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10798 holding.
  • Citadel Advisors first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
  • Citadel Advisors's Atea Pharmaceuticals position peaked at $14.9M in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.